Translate Register Log In Login with facebookLogin and Register

Higher Vitamin D increased the benefit of anti-TNF- α drug used for IBD by 2.6 times – Jan 2017

Higher 25-hydroxyvitamin D levels are associated with greater odds of remission with anti-tumour necrosis factor-α medications among patients with inflammatory bowel diseases

Alimentary Pharmacology & Therapeutics, DOI: 10.1111/apt.13936
R. W. Winter, E. Collins, B. Cao, M. Carrellas, A. M. Crowell, J. R. Korzenik


"Higher" is > 33 ng of vitamin D
Note: Perhaps those with higher vitamin D did not even need the anti-TNF

Studies which are in both categories of Intervention AND Gut

Studies which are in both categories of Intervention AND Rheumatoid Arthritis

Studies which are in both categories of Intervention AND Psorasis

See also web

  • TNF Inhibitor Wikipedia
    “A TNF inhibitor is a pharmaceutical drug that suppresses the physiologic response to tumor necrosis factor (TNF), which is part of the inflammatory response. TNF is involved in autoimmune and immune-mediated disorders such as rheumatoid arthritis, ankylosing spondylitis, inflammatory bowel disease, psoriasis, hidradenitis suppurativa and refractory asthma.”
  • Nutraingredients discussion of this study

 Download the PDF from VitaminDWiki

Vitamin D has been linked to disease activity among patients with inflammatory bowel diseases (IBD). Prior investigation has also suggested that vitamin D levels may affect duration of therapy with anti-tumour necrosis factor-α (anti-TNF-α) medications among patients with IBD.

To evaluate the relationship between vitamin D levels and odds of reaching remission while on an anti-TNF-α medication.

A total of 521 IBD patients enrolled in the Brigham and Women's IBD Centre database were eligible for inclusion. Patients treated with anti-TNF-α therapy who had vitamin D levels drawn within 6 months prior or 2 weeks after initiation of anti-TNF-α medication and who had reported remission status at 3 months were included. A logistic regression model adjusting for age, gender, IBD diagnosis, anti-TNF-α medication (infliximab vs. adalimumab) and first or subsequent anti-TNF-α medication was used to identify the effect of vitamin D level on initial response to anti-TNF-α therapy.

A total of 173 patients were included in the final analysis. On logistic regression, patients with normal vitamin D levels n = 122 at the time of anti-TNF-α medication initiation had a 2.64 increased odds of remission at 3 months compared to patients with low vitamin D levels n = 51 when controlling for age, gender, diagnosis, type of anti-TNF-α medication and first or subsequent anti-TNF-α medication (OR = 2.64, 95% CI = 1.31–5.32, P = 0.0067).

These findings suggest that vitamin D levels may influence initial response to anti-TNF-α medication and that low vitamin D levels may pre-dispose patients to decreased odds of remission.

Attached files

ID Name Comment Uploaded Size Downloads
7735 TNF IBD.pdf PDF 2017 admin 31 Jan, 2017 20:52 142.32 Kb 236
See any problem with this page? Report it (FINALLY WORKS)